Sugi Predict

Sugi Predict / Compounds / SCHEMBL6797321

SCHEMBL6797321

SCHEMBL6797321

O=[N+]([O-])c1cccnc1Nc1cccc(-c2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.55
▸ KMT2A Q03164 3/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ ABCG2 Q9UNQ0 6/20 0.51
▸ NPC1 O15118 4/20 0.50
▸ RAB9A P51151 4/20 0.50
▸ ALDH1A1 P00352 3/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ NFKB2 Q00653 1/20 0.48
▸ RELA Q04206 1/20 0.48
▸ KCNH2 Q12809 1/20 0.48
▸ GSK3B P49841 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ EGFR P00533 1/20 0.45
▸ PIN1 Q13526 1/20 0.45
▸ ALOX5 P09917 1/20 0.45
▸ PDE5A O76074 1/20 0.44
▸ CASP7 P55210 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6798323 0.99 MAPT (0.54) MAPTKMT2AMEN1L3MBTL1ABCG2
SCHEMBL6795443 0.92 MAPT (0.53) MAPTKMT2AMEN1L3MBTL1ABCG2
SCHEMBL7357488 0.90 MAPT (0.56) MAPTKMT2AMEN1L3MBTL1ABCG2
SCHEMBL6797852 0.89 MAPT (0.50) MAPTKMT2AMEN1L3MBTL1ABCG2
SCHEMBL6798244 0.88 MAPT (0.52) MAPTKMT2AMEN1L3MBTL1ABCG2
SCHEMBL6796955 0.88 ABCG2 (0.53) MAPTKMT2AMEN1L3MBTL1ABCG2
SCHEMBL2177925 0.87 MAPT (0.69) MAPTKMT2AMEN1L3MBTL1NPC1
SCHEMBL6804477 0.85 MAPT (0.49) MAPTKMT2AMEN1L3MBTL1ABCG2
SCHEMBL6798198 0.85 MAPT (0.49) MAPTKMT2AMEN1L3MBTL1ABCG2
SCHEMBL6792229 0.85 MEN1 (0.59) MAPTKMT2AMEN1L3MBTL1ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11600791-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-03-07 — — US disclosed
EP-3936512-A1 PYRIDYL CARBENE PHOSPHORESCENT EMITTERS Universal Display Corporation (US) 2022-01-12 — — EP disclosed
EP-3936512-A1 PYRIDYL CARBENE PHOSPHORESCENT EMITTERS Universal Display Corporation (US) 2022-01-12 — — EP disclosed
EP-3424935-B1 IMIDAZOPYRAZINYL CARBENE PHOSPHORESCENT EMITTERS UNIVERSAL DISPLAY CORP (US) 2021-08-11 — — EP disclosed
EP-3424935-B1 IMIDAZOPYRAZINYL CARBENE PHOSPHORESCENT EMITTERS UNIVERSAL DISPLAY CORP (US) 2021-08-11 — — EP disclosed
US-20210050530-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2021-02-18 — — US disclosed
US-20210050530-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2021-02-18 — — US disclosed
US-10873038-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2020-12-22 — — US disclosed
US-10873038-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2020-12-22 — — US disclosed
US-20190109287-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2019-04-11 — — US disclosed
US-20120228583-A1 PYRIDYL CARBENE PHOSPHORESCENT EMITTERS UNIVERSAL DISPLAY CORPORATION (US) 2012-09-13 — — US disclosed
US-20120228583-A1 PYRIDYL CARBENE PHOSPHORESCENT EMITTERS UNIVERSAL DISPLAY CORPORATION (US) 2012-09-13 — — US disclosed
US-20120228583-A1 PYRIDYL CARBENE PHOSPHORESCENT EMITTERS UNIVERSAL DISPLAY CORPORATION (US) 2012-09-13 — — US disclosed
US-6727245-B2 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-04-27 — — US disclosed
EP-0770079-B1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2003-02-12 — — EP disclosed
US-20020107251-A1 Heterobicyclic derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-08-08 — — US disclosed
US-6426345-B1 PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-30 — — US disclosed
EP-0920867-A1 Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-06-09 — — EP disclosed
EP-0770079-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-05-02 — — EP disclosed
WO-1996001825-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210050530-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES NUDC, NCL, NDC1 MAPT 608/4885KMT2A 3120/4885MEN1 2130/4885
US-10873038-B2 Organic electroluminescent materials and devices NUDC, NCL, NDC1 MAPT 608/4885KMT2A 3120/4885MEN1 2130/4885
US-20120228583-A1 PYRIDYL CARBENE PHOSPHORESCENT EMITTERS PAICS, PIR, NUDC MAPT 672/4885KMT2A 3226/4885MEN1 2060/4885
US-20190109287-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES NUDC, NCL, NDC1 MAPT 608/4885KMT2A 3120/4885MEN1 2130/4885
US-11600791-B2 Organic electroluminescent materials and devices NUDC, NCL, NDC1 MAPT 608/4885KMT2A 3120/4885MEN1 2130/4885
US-20020107251-A1 Heterobicyclic derivatives ARSA, ARRB1, SULT2A1 MAPT 4677/4885KMT2A 968/4885MEN1 2703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.